A large scale study of angiotensin II inhibition therapy in an elderly population: the CHANCE study
| Autor: | Sophie Nisse-Durgeat, Roland Asmar |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Male
medicine.medical_specialty hypertension Endocrinology Diabetes and Metabolism Diastole Urology Tetrazoles Blood Pressure Diabetic angiopathy Angiotensin Receptor Antagonists Internal medicine medicine Humans Pharmacology (medical) Antihypertensive Agents Aged Original Research Dose-Response Relationship Drug CHANCE study business.industry Biphenyl Compounds Public Health Environmental and Occupational Health elderly subject Hematology General Medicine angiotensin II receptor antagonist medicine.disease candesartan cilexetil Angiotensin II Pulse pressure Biphenyl compound Dose–response relationship Candesartan Blood pressure Endocrinology Benzimidazoles Female Cardiology and Cardiovascular Medicine business Diabetic Angiopathies medicine.drug |
| Zdroj: | Vascular Health and Risk Management |
| ISSN: | 1176-6344 |
| Popis: | This 8-week, multicenter study evaluated the efficacy and safety of candesartan cilexetil (CC, 8-16 mg) in elderly (65 years) hypertensive patients. Patients (n=3013) received CC 8 mg during 8 weeks which eventually doubled to CC 16 mg at week 4 if blood pressure remained uncontrolled (or = 140/90 mmHg). At week 8, 65.5% of patients were normalized (BP140/90 mmHg). Mean changes at week 8 were -25.8, -13.2, and -12.7 mmHg for systolic, diastolic, and pulse pressure, respectively. Age, sex, and diabetic status did not influence the antihypertensive effect of CC. 68% of the patients treated with, but uncontrolled or intolerant of, prior antihypertensive treatment were normalized by CC 8-16 mg. In summary, CC 8-16 mg once daily was effective and well tolerated in the management of arterial hypertension in elderly subjects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|